Clinical Trials » Macular Degeneration
RetinoStat® Gene Therapy for the Treatment of Wet AMD: Oxford BioMedica
|
RECRUITING Description: Oxford BioMedica (U.K.) is conducting a Phase I clinical trial of RetinoStat® for the treatment of wet age-related macular degeneration (AMD). The treatment involves the delivery of a gene that produces a protein which halts the production of vascular endothelial growth factor (VEGF). VEGF is a protein that leads to the proliferation of leaky blood vessels underneath the retina that causes vision loss in wet AMD. A lentivisrus is used for gene delivery. As many as 18 participants will be enrolled in the study. Three doses of the treatment are being evaluated. Trial Status: Recruiting participants. Article: Clinical Trial for Wet AMD Gene Therapy to Begin in December 2010 Partial List of Participation Criteria:
Peter Campochiaro, M.D. This e-mail address is being protected from spambots. You need JavaScript enabled to view it Johns Hopkins University Hospital Baltimore, MD Additional Information: RetinoStat clinical trial listing on ClinicalTrials.gov |
